Prosecutors don't know where Kenosha shooter Kyle Rittenhouse is?IBTimes IN

Pfizer has decided to withdraw its application for Emergency Use Authorisation of its Covid-19 vaccine in India.

"In pursuance of the Emergency Use Authorisation of its Covid-19 vaccine, Pfizer participated in the Subject Expert Committee meeting of the Drug Regulatory Authority of India on February 3. Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time," a Pfizer spokesperson said.

"Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes available in the near future. Pfizer remains committed to making its vaccine available for use by the Government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment," the spokesperson said.

Pfizer had sought authorisation for its vaccine in India late last year

Pfizer had sought authorisation for its vaccine in India late last year, but the government in January approved two much cheaper shots - one from Oxford University/AstraZeneca and another developed at home by Bharat Biotech with the Indian Council of Medical Research. Both companies had applied for approval of their vaccines after Pfizer.

India's Central Drugs Standard Control Organisation had declined to accept Pfizer's request for approval without a small local trial on the vaccine's safety and immunogenicity for Indians, Reuters has reported.

Indian health officials say they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in its citizens whose genetic makeup can be different from people in Western nations. There are, however, provisions under India's New Drugs and Clinical Trial Rules, 2019, to waive such trials in certain conditions.

Pfizer earlier told Reuters its application was supported by data from a global study that showed an overall efficacy rate of 95% with no vaccine-related, serious safety concerns.

(With inputs from Reuters) 

  • Pfizer acts cocky with India: Order first, will seek COVID vaccine approval later
  • COVID vaccine linked to 23 deaths in Norway; causes global panic [details]
  • Now a doctor dies after receiving Pfizer's coronavirus vaccine; probe ordered [Details]
  • Covaxin can work on UK strain, no way inferior to Pfizer's, says Bharat Biotech
  • Health worker dies two days after receiving Pfizer's COVID vaccine